Lipocine Inc. (LPCN)

Price$2.30

Favorite Metrics

Price vs S&P 500 (26W)-30.36%

Price vs S&P 500 (4W)-75.51%

Market Capitalization$16.86M

P/E Ratio (Annual)6416.73x

All Metrics

Book Value / Share (Quarterly)$2.35

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.12%

Cash Flow / Share (Quarterly)$-1.58

Price vs S&P 500 (YTD)-73.88%

Net Profit Margin (TTM)-487.06%

EPS (TTM)$-1.77

10-Day Avg Trading Volume1.11M

EPS Excl Extra (TTM)$-1.77

Revenue Growth (5Y)133.89%

EPS (Annual)$-1.77

ROI (Annual)-66.50%

Net Profit Margin (5Y Avg)-2154.83%

Cash / Share (Quarterly)$2.42

Revenue Growth QoQ (YoY)-67.19%

P/E Normalized (Annual)6416.73x

ROA (Last FY)-56.61%

Revenue Growth TTM (YoY)-82.35%

EBITD / Share (TTM)$-1.89

ROE (5Y Avg)-35.66%

Operating Margin (TTM)-524.69%

Cash Flow / Share (Annual)$-1.58

P/B Ratio1.16x

P/B Ratio (Quarterly)3.08x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)5.90x

Net Interest Coverage (TTM)-3.50x

ROA (TTM)-53.37%

EV / EBITDA (TTM)3.01x

EPS Incl Extra (Annual)$-1.77

Current Ratio (Annual)6.68x

Quick Ratio (Quarterly)6.36x

3-Month Avg Trading Volume0.33M

52-Week Price Return-19.27%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.23

P/S Ratio (Annual)8.53x

Asset Turnover (Annual)0.12x

52-Week High$12.37

Operating Margin (5Y Avg)-2195.35%

EPS Excl Extra (Annual)$-1.77

Tangible BV CAGR (5Y)13.43%

26-Week Price Return-21.61%

Quick Ratio (Annual)6.36x

13-Week Price Return-77.91%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.68x

Enterprise Value$11.656

Revenue / Share Growth (5Y)81.34%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-8.79%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-487.04%

Cash / Share (Annual)$2.42

3-Month Return Std Dev175.50%

Net Income / Employee (TTM)$-1

ROE (Last FY)-66.50%

Net Interest Coverage (Annual)-3.57x

EPS Basic Excl Extra (Annual)$-1.77

P/FCF (TTM)4.12x

Receivables Turnover (TTM)29.36x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.77

Receivables Turnover (Annual)29.36x

ROI (TTM)-59.29%

P/S Ratio (TTM)8.53x

Pretax Margin (5Y Avg)-2154.82%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$6.84

Price vs S&P 500 (52W)-54.36%

Year-to-Date Return-69.74%

5-Day Price Return2.10%

EPS Normalized (Annual)$-1.77

ROA (5Y Avg)-31.50%

Net Profit Margin (Annual)-487.05%

Month-to-Date Return-69.59%

Cash Flow / Share (TTM)$-3.09

EBITD / Share (Annual)$-1.89

Operating Margin (Annual)-524.69%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-35.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.77

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)3.08x

Pretax Margin (TTM)-487.05%

Book Value / Share (Annual)$2.35

Price vs S&P 500 (13W)-80.77%

Beta0.56x

Revenue / Share (TTM)$0.35

ROE (TTM)-59.29%

52-Week Low$1.81

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LPCNLipocine Inc.	8.53x	-82.35%	—	—	$2.30
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Lipocine is a clinical-stage biopharmaceutical company developing oral drug delivery solutions using proprietary technology. Its lead product, TLANDO, is an oral testosterone replacement therapy. The company is advancing a pipeline of additional candidates including TLANDO XR and compounds designated LPCN 1144, LPCN 1148, LPCN 1107, and LPCN 1154, developed both internally and in collaboration with corporate partners.